Slide 1

Topline LIBERTY Data & VYD2311 Next Steps September 29, 2026 ©2026 Invivyd, Inc. Invivyd is a registered trademark of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners. Exhibit 99.2

Slide 2

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “seek,” “could,” “intend,” “target,” “aim,” “project,” “designed to,” “estimate,” “believe,” “predict,” “potential,” or “continue” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements include statements concerning, among other things, the company’s vision; plans related to the company’s research and development activities, and the timing and potential results thereof, including with respect to the DECLARATION pivotal clinical trial; expectations regarding the company’s anticipated regulatory pathway, product profile, indication, patient populations, and administration paradigm for VYD2311, including the company’s belief that VYD2311 meets and exceeds the criteria for Accelerated Approval and its plans to submit a Biologics License Application (BLA) for VYD2311 to the U.S. Food and Drug Administration (FDA) via Accelerated Approval Program; the company’s beliefs about the implications of topline LIBERTY study data; expectations regarding the public health landscape, potential advantages of monoclonal antibodies (mAbs), and potential complementarity between vaccines and Invivyd mAbs; the potential of VYD2311 as a novel mAb candidate that may be able to deliver clinically meaningful titer levels through more patient-friendly means, and expectations about the clinical profile of VYD2311; the company’s strategies and objectives; the company’s future prospects; and other statements that are not historical fact. The company may not actually achieve the plans, intentions, or expectations disclosed in the company’s forward-looking statements and you should not place undue reliance on the company’s forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the company’s actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation: the timing, progress, and results of the company’s discovery, preclinical, and clinical development activities, including implementation of any necessary protocol amendments; uncertainties regarding clinical trial event accumulation rates and statistical powering; the risk that results of nonclinical studies or clinical trials may not be predictive of future results, and interim data are subject to further analysis; unexpected safety or efficacy data observed during preclinical studies or clinical trials; the predictability of clinical success of the company’s product candidates based on neutralizing activity in nonclinical studies; changes in the regulatory environment; the outcome of the company’s engagement with regulators; uncertainties related to the regulatory approval process, and available development and regulatory pathways; the company’s ability to generate the data needed to support its planned BLA submission for VYD2311, and uncertainties regarding the FDA’s acceptance and review of any such BLA submission; potential variability in neutralizing activity of product candidates tested in different assays, such as pseudovirus assays and authentic assays; variability of results in models and methods used to predict activity against SARS-CoV-2 variants; whether the epitope that VYD2311 targets remains structurally intact and the company’s product candidates are able to demonstrate and sustain neutralizing activity against major SARS-CoV-2 variants, particularly in the face of viral evolution; the ability to maintain a continued acceptable safety, tolerability, and efficacy profile of any product candidate following regulatory authorization or approval; the risk that a lack of awareness of mAb therapies and regulatory scrutiny of mAb therapies may adversely impact the development or commercial success of the company’s product candidates; changes in expected or existing competition; the company’s reliance on third parties; complexities of manufacturing mAb therapies; macroeconomic and political uncertainties; and whether the company has adequate funding to meet future operating expenses and capital expenditure requirements. Other factors that may cause the company’s actual results to differ materially from those expressed or implied in the forward-looking statements in this presentation are described under the heading “Risk Factors” in the company’s Annual Report on Form 10-K for the year ended December 31, 2025, and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, each as filed with the Securities and Exchange Commission (SEC), and in the company’s other filings with the SEC, and in its future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this press release are made as of this date, and Invivyd undertakes no duty to update such information whether as a result of new information, future events or otherwise, except as required under applicable law. This presentation contains hyperlinks to information that is not deemed to be incorporated by reference in this presentation. All trademarks used in this presentation are the property of their respective owners.

Slide 3

agenda Executive Summary LIBERTY Topline Data Regulatory & Next Steps Q&A

Slide 4

Invivyd Vision Antibody supplementation as a new step forward in the human fight against infectious disease 4

Slide 5

VYD2311 met all primary and secondary endpoints in the Phase 3 LIBERTY study, with a clinically and statistically superior safety and tolerability profile relative to an mRNA COVID-19 vaccine VYD2311 observed profile in LIBERTY indicates high measured neutralizing antiviral activity supporting the target profile for VYD2311 under study in the DECLARATION pivotal clinical study Planned Biologics License Application (BLA) submission to the U.S. FDA via Accelerated Approval pathway on the basis of DECLARATION sVNA titers, PK, and safety data and LIBERTY data DECLARATION sVNA titers, PK, and safety data expected in October 2026; COVID-19 events to remain blinded and DECLARATION planned to serve as the ongoing, confirmatory trial Executive summary VYD2311 combined with an mRNA-based COVID-19 vaccine demonstrated no evidence of interference with vaccine-induced neutralizing titers and added substantially to vaccine-induced neutralizing titers  sVNA: serum virus neutralizing antibody; PK: Pharmacokinetics.

Slide 6

agenda Executive Summary LIBERTY Topline Data Regulatory & Next Steps Q&A

Slide 7

RAT: Rapid Antigen Test; BMI: body mass index. Note: mRNA vaccine COMIRNATY® (COVID-19 vaccine, mRNA) was utilized in the LIBERTY study. All subjects were dosed using intramuscular needles consistent with COVID-19 vaccination, and, for blinding purposes, placebo injections were volume-matched to either VYD2311 (2mL) or COVID-19 vaccine (0.5mL). Co-Primary Endpoints: The proportion of subjects experiencing a treatment-emergent adverse event, injection site reaction, or hypersensitivity reaction over the first 6 days post-administration The proportion of subjects experiencing a systemic adverse event solicited via an e-diary over the first 6 days post-administration A Phase 3, Randomized, Double-Blind Clinical Trial to Evaluate Head-to-Head Safety & Tolerability and Co-Administration Interaction of VYD2311 with mRNA-based COVID Vaccines in Adults Screening (up to Day -14) R 1:1:1 N=210 VYD2311 (250 mg single dose) + IM Placebo mRNA Vaccine (single dose) + IM Placebo Combination 250 mg VYD2311 and mRNA Vaccine Follow-Up Period Day 0 Day 56 Diary Day 6 Key Inclusion Criteria: 18 to 49 years BMI 18 to 32 No prior use of VYD2311 or pemivibart X ≥6 months since last COVID-19 vaccine; ≥28 days since non-COVID-19 vaccine Negative RAT test on day 1 Ongoing collection of TEAEs, blood draws, physical exams, & vital signs; weekly SARS-CoV-2 RAT

Slide 8

Baseline characteristics were well-balanced across LIBERTY study arms VYD2311 Only (N=69) Vaccine Only (N=70) Combination (N=71) Sex (% Female) 41% 50% 39% Age (Years) - Mean 34.9 33.8 35.4 Race (%) White (%) 46% 44% 42% Black (%) 42% 44% 49% Other & Unknown (%) 12% 12% 9% Weight (kg) - Mean 77.2 77.1 78.6 BMI (kg/m2) - Mean 26.1 26.2 26.4 BMI: body mass index.

Slide 9

VYD2311 monotherapy met both co-primary endpoints when compared to an mRNA-based COVID-19 vaccine TEAE: treatment-emergent adverse event; ISR: injection site reaction; AE: adverse event. Note: mRNA vaccine COMIRNATY® (COVID-19 vaccine, mRNA) was utilized in the LIBERTY study. No hypersensitivity or anaphylaxis was observed in any arm of the LIBERTY study Co-Primary Endpoints Treatment Arm (% of Subjects) Comparator Arm (% of Subjects) P-value Short Term (6 Days) Overall Safety and Tolerability % of subjects experiencing any TEAE, ISR, or hypersensitivity for 6 days post-administration VYD2311 (56.5%) COVID-19 Vaccine (91.4%) p < 0.0001 Short Term (6 Days) Systemic AEs % of subjects experiencing systemic AEs solicited via e-diary for 6 days post-administration VYD2311 (44.1%) COVID-19 Vaccine (68.1%) p = 0.008 Key Secondary Endpoint Long Term (56 Days) Overall Safety and Tolerability % of subjects experiencing any TEAE, ISR, or hypersensitivity for 56 days post-administration VYD2311 (60.9%) COVID-19 Vaccine (91.4%) p < 0.0001

Slide 10

The addition of VYD2311 to an mRNA COVID-19 vaccine may improve the safety and tolerability of the mRNA COVID vaccine alone Co-Primary Endpoints Treatment Arm (% of Subjects) Comparator Arm (% of Subjects) P-value Short Term (6 Days) Overall Safety and Tolerability % of subjects experiencing any TEAE, ISR, or hypersensitivity for 6 days post-administration Combo (78.9%) COVID-19 Vaccine (91.4%) p = 0.057 Short Term (6 Days) Systemic AEs % of subjects experiencing systemic AEs solicited via e-diary for 6 days post-administration Combo (50.0%) COVID-19 Vaccine (68.1%) p = 0.023 Key Secondary Endpoint Long Term (56 Days) Overall Safety and Tolerability % of subjects experiencing any TEAE, ISR, or hypersensitivity for 56 days post-administration Combo (83.1%) COVID-19 Vaccine (91.4%) p = 0.21 TEAE: treatment-emergent adverse event; ISR: injection site reaction; AE: adverse event. Note: mRNA vaccine COMIRNATY® (COVID-19 vaccine, mRNA) was utilized in the LIBERTY study.

Slide 11

VYD2311 demonstrated benefit compared to mRNA COVID-19 vaccine across multiple endpoints VYD2311 mRNA COVID-19 Vaccine Combination Subjects with Event (%) Adverse Event Incidence by Arm: First 7 Days

Slide 12

Assessment of immunologic interference experimental design Clinical Sample from VYD2311 & COVID-19 Vaccine Combination Arm VYD2311 + anti-VYD2311 Complex (REMOVED) Vaccine-Induced Titers Only from Combination Sample for Comparison to Vaccine-Only Samples Add anti-VYD2311 Antibody & Perform Separation VYD2311 Anti-VYD2311 Antibody Vaccine-Induced Antibody

Slide 13

Combination delivery of VYD2311 and mRNA-based COVID vaccine appears to have no effect on vaccine-derived neutralizing response and to increase total titers *Both arms identically treated with VYD2311 depleting reagents.

Slide 14

VYD2311 exhibited more favorable safety and tolerability compared to the mRNA COVID-19 vaccine, supporting the potential for VYD2311 to offer a clinically meaningful advantage over the current standard-of-care No evidence of immunologic interference was observed between VYD2311 and mRNA COVID-19 vaccine, indicating no challenge to combination use if desired Upcoming DECLARATION data should further elaborate on safety and efficacy profile of VYD2311 Key takeaways & implications Co-administration of VYD2311 and mRNA COVID-19 vaccine produced several-fold higher total neutralizing titers than vaccine alone, with numerically lower TEAEs, suggesting the potential to use monoclonal antibody technology to improve the clinical profile of various vaccines

Slide 15

agenda Executive Summary LIBERTY Topline Data Regulatory & Next Steps Q&A

Slide 16

Recall VYD2311 is simply the latest in a series of functionally identical, clinically-validated Invivyd monoclonal antibodies Adintrevimab Fv Bound to Wuhan (WT) RBD Pemivibart Fv Bound to Omicron BA.5 RBD VYD2311 Fv Bound to XEC RBD 71% Reduction in risk of symptomatic COVID-19 at 90 days* 94% Reduction in risk of symptomatic COVID-19 at 90 days* PENDING EVADE Phase 2/3 · PrEP cohort CANOPY Phase 3 · PrEP DECLARATION Phase 3 · PrEP *Figures provided represent relative risk reduction versus placebo in immunocompetent cohort. RBD: Receptor binding domain; PrEP: Pre-exposure prophylaxis.

Slide 17

Binding and neutralization across all Invivyd COVID antibodies is geometrically identical at the level x-ray crystallography Adintrevimab, Pemivibart, and VYD2311 Superimposed on Target: +/- 0.5A Each COVID mAb was minimally evolved to ensure the preservation of the clinically-validated biological interface between antibody and evolving virus The result is functionally identical antibodies with a consistent interface and mechanism This approach should minimize biological uncertainty and provide high confidence in clinical benefit across antibodies

Slide 18

We believe as a consequence that the resulting antiviral titers from our antibodies are highly reliable predictors of clinical protection The relationship between neutralizing titers and protection from symptomatic COVID-19 is now well established in two peer-reviewed correlate-of-protection analyses based off data from two RCTs Yalcin et al. Immune Correlates of Protection Model, CANOPY (2026) Schmidt et al. Science, EVADE (2023) RCT: Randomized Controlled Trial; sVNA: serum virus neutralizing antibody. Sources: Schmidt, et al. Sci Transl Med. 2023. DOI: 10.1126/scitranslmed.adg2783; Yalcin. Infect Dis Ther. 2026. Invivyd sVNA titers act as a direct, highly reliable predictor of clinical efficacy because our COVID antibodies preserve a constant physiologic interface and a consistent mechanism

Slide 19

We believe VYD2311 meets and exceeds the criteria for Accelerated Approval IC: Immunocompromised; EUA: Emergency Use Authorization; sVNA: serum virus neutralizing antibody. Sources: FDA. “ Guidance Document: Accelerated Approval – Expedited Program for Serious Conditions” Published December 2024. Fast Track designation for VYD2311 establishes the FDA’s view that COVID is a serious condition with unmet medical need Excess severe outcomes and mortality persist across variant eras, despite high population immunity IC patients remain at high risk for severe complications, do not respond optimally to vaccines, and have no other options Targets a Serious Condition & Unmet Need Surrogate Endpoint Reasonably Likely to Predict Clinical Benefit Requires an effect on a surrogate marker reasonably likely to predict clinical benefit, supported by at least one of the following criteria: Pathophysiologic: Assay measurement confirms the directly administered antibody actively neutralizes the virus Therapeutic: Four RCTs demonstrated relationship of sVNA titers to clinical benefit for mAbs with a shared epitope, geometry, interface, and assay Epidemiologic: Peer-reviewed publications statistically validate Invivyd sVNA titers as a predictor of clinical benefit The LIBERTY data demonstrated a meaningful improvement in the safety and tolerability profile of VYD2311 compared to the Standard of Care IC patients fail to respond adequately to vaccination; following termination of PEMGARDA® EUA in June 2027, IC population will not have suitable COVID prevention options Meaningful Advantage Over Available Therapy Confirmatory Trial Underway Any residual uncertainty as to the relation of VYD2311 titer to clinical benefit will be verified and described through the ongoing randomized, double-blind DECLARATION trial (n=2,386) DECLARATION trial planned as confirmatory study; ongoing, with blinded accumulated clinical events 19

Slide 20

Preparations underway for VYD2311 Accelerated Approval BLA submission Unblind and report the placebo-controlled safety and immunogenicity data from DECLARATION Move to submitting Biologics License Application (BLA) as soon as possible Continue commercial preparation for VYD2311 20

Slide 21

agenda Executive Summary LIBERTY Topline Data Regulatory & Next Steps Q&A

Slide 22

Q&A

Slide 23